Ethosuximide (All indications) updated on 04-22-2025

Intrauterine deaths (as a whole or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16752
R70380		 Vajda a (Ethosuximide) (Controls exposed to LTG) (Epilepsy), 2024 Intra uterine foetal death (including both spontaneous abortions and stillbirths, but not elective termination) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 33.32 [0.63;1770.12] C
excluded (control group) 		1/1   10/326 11 1
ref
S16199
R67129		 Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024 Intra uterine foetal death (including both spontaneous abortions and stillbirths, but not elective termination) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No no data 1/1   0/149 1 1
ref
Total 1 studies NaN [NaN;NaN] 1 1
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024Vajda a, 2024 1 Out of scale-299.00[NaN; NaN]110%ROB confusion: criticalROB selection: criticalROB classification: unclearROB missing: unclearROB mesure: criticalROB reporting: moderate0.02.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Ethosuximide) (Controls unexposed sick) (Epilepsy;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024 1 Tags Adjustment   - No  - No Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024 1 All studiesAll studies Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024 10.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16752

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale33.32[0.63; 1770.12]111 -NAVajda a (Ethosuximide) (Controls exposed to LTG) (Epilepsy), 2024 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (NMA) (All indications) (Combined ...Veroniki a (NMA) (All indications) (Combined fetal losses) 2.12[0.27; 9.07]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg Vajda a (Ethosuximide) (Controls unexposed sick) (Epilepsy), 2024 10.510.01.0